Amanda Winters

Assistant Professor

University of Colorado Anschutz Medical Campus

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Amanda Winters is an Assistant Professor at the University of Colorado - Anschutz Medical Campus in the United States. Her research focuses on pediatric oncology, specifically the treatment and outcomes of acute myeloid leukemia and related conditions. Recent publications include investigations into transfusion-related iron overload, neurocognitive dysfunction in children with various malignancies, and targeted therapies for leukemia stem cells.

Articles (12)

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Daniel A. Pollyea

UNITED STATES

View details

Claire Miller

Assistant Professor

University of Utah

UNITED STATES

View details

craig jordan

Professor

University of Colorado School of Medicine

UNITED STATES

View details

Christopher McKinney

University of Colorado Anschutz Medical Campus

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Amanda Winters

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Risk of transfusion‐related iron overload varies based on oncologic diagnosis and associated treatment: Retrospective analysis from a single pediatric cancer center

Identifying patterns of neurocognitive dysfunction through direct comparison of children with leukemia, central nervous system tumors, and sickle cell disease

Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells

Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60

Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy

Importance of clinical correlation in the diagnosis of pediatric B‐cell lymphomas

The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation

Venetoclax and Azacitidine Compared to Induction Chemotherapy for Newly Diagnosed Patients with Acute Myeloid Leukemia.

The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia.

Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.

Single‐center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia

Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.

Collaborators (4)

Daniel A. Pollyea

Claire Miller

craig jordan

Christopher McKinney

Make your next move.